Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

Understanding what happens when obesity treatment is continued versus discontinued is critical for long-term treatment planning. The STEP 4 trial by Rubino, Abrahamsson, Davies, and colleagues, published in JAMA, specifically examined the effects of continued versus withdrawn semaglutide therapy on weight loss maintenance.

The randomized clinical trial first treated all participants with semaglutide for an initial period, then randomized them to either continue treatment or switch to placebo. This withdrawal design directly measured the contribution of ongoing therapy to weight maintenance.

The STEP 4 results confirmed that continued semaglutide treatment is critical for maintaining weight loss. Participants who continued therapy preserved significantly greater weight reductions than those switched to placebo, who experienced substantial weight regain.

This study provides essential guidance for both clinicians and patients regarding treatment duration expectations. The clear demonstration that sustained semaglutide therapy is necessary for maintaining weight loss helps set realistic expectations and supports long-term treatment strategies that maximize the enduring benefits of this therapy.